{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:02:48Z","timestamp":1792501368425,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"am","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.revmed.2020.02.015","type":"journal-article","created":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T01:58:22Z","timestamp":1584410302000},"page":"421-424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Dermatomyosite \u00e0 anticorps anti-MDA5\u00a0s\u00e9v\u00e8re associ\u00e9e \u00e0 un cancer et contr\u00f4l\u00e9e par inhibiteur de JAK"],"prefix":"10.1016","volume":"41","author":[{"given":"C.","family":"Jalles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Deroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tardieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lugosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Viel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Colombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.revmed.2020.02.015_bib0005","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00296-018-3991-7","article-title":"Rapidly progressive interstitial lung disease due to anti-MDA5\u00a0antibodies without skin involvement: a case report and literature review","volume":"38","author":"Gonz\u00e1lez-Moreno","year":"2018","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.revmed.2020.02.015_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"1\u20132","key":"10.1016\/j.revmed.2020.02.015_bib0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med Camb Mass"},{"issue":"1","key":"10.1016\/j.revmed.2020.02.015_bib0020","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/art.40328","article-title":"Myogenic Progenitor Cells Exhibit Type I Interferon-Driven Proangiogenic Properties and Molecular Signature During Juvenile Dermatomyositis","volume":"70","author":"Gitiaux","year":"2018","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"1","key":"10.1016\/j.revmed.2020.02.015_bib0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/14397595.2014.900843","article-title":"Serum interferon-\u03b1 is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis","volume":"25","author":"Horai","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.revmed.2020.02.015_bib0030","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/bjd.16917","article-title":"Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5\u00a0dermatomyositis","volume":"180","author":"Zhang","year":"2019","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.revmed.2020.02.015_bib0035","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain J Neurol"},{"issue":"1","key":"10.1016\/j.revmed.2020.02.015_bib0040","doi-asserted-by":"crossref","first-page":"e29161","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.revmed.2020.02.015_bib0045","first-page":"1","article-title":"Anti-MDA5\u00a0juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-a signalling","volume":"0","author":"Melki","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.revmed.2020.02.015_bib0050","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cyto.2018.10.023","article-title":"Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies","volume":"113","author":"Pescarmona","year":"2019","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.revmed.2020.02.015_bib0055","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/rheumatology\/key386","article-title":"The relationship between type 1\u00a0IFN and vasculopathy in anti-MDA5\u00a0antibody-positive dermatomyositis patients","volume":"58","author":"Ono","year":"2019","journal-title":"Rheumatol Oxf Engl"},{"issue":"26","key":"10.1016\/j.revmed.2020.02.015_bib0060","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with ruxolitinib","volume":"371","author":"Hornung","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.revmed.2020.02.015_bib0065","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1093\/brain\/awy255","article-title":"A child with severe juvenile dermatomyositis treated with ruxolitinib","volume":"141","author":"Aeschlimann","year":"2018","journal-title":"Brain J Neurol"},{"issue":"8","key":"10.1016\/j.revmed.2020.02.015_bib0070","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.revmed.2020.02.015_bib0075","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5\u00a0gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatol Oxf Engl"},{"issue":"4","key":"10.1016\/j.revmed.2020.02.015_bib0080","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.semarthrit.2016.08.009","article-title":"A case of refractory dermatomyositis responsive to tofacitinib","volume":"46","author":"Paik","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.revmed.2020.02.015_bib0085","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/brain\/awz293","article-title":"Treatment of anti-MDA5\u00a0autoantibody-positive juvenile dermatomyositis using tofacitinib","volume":"142","author":"Sabbagh","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.revmed.2020.02.015_bib0090","article-title":"Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5\u00a0Antibody-Positive Dermatomyositis","author":"Kato","year":"2019","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"issue":"3","key":"10.1016\/j.revmed.2020.02.015_bib0095","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.revmed.2020.02.015_bib0100","first-page":"5960","article-title":"Characteristics and predictors of malignancy in dermatomyositis: analysis of 239\u00a0patients from northern China","volume":"16","author":"Liu","year":"2018","journal-title":"Oncol Lett"},{"issue":"3","key":"10.1016\/j.revmed.2020.02.015_bib0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/25785826.2018.1531188","article-title":"Clinical significance of myositis-specific autoantibodies","volume":"41","author":"Nakashima","year":"2018","journal-title":"Immunol Med"},{"issue":"3","key":"10.1016\/j.revmed.2020.02.015_bib0110","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1684\/ejd.2018.3287","article-title":"Anti-MDA5\u00a0antibody-positive bullous dermatomyositis with thyroid carcinoma","volume":"28","author":"Hayami","year":"2018","journal-title":"Eur J Dermatol EJD"},{"issue":"10","key":"10.1016\/j.revmed.2020.02.015_bib0115","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.annder.2017.05.009","article-title":"Amyopathic dermatomyositis (DM) with anti-MDA5\u00a0antibodies, associated with bullous pemphigoid, Sj\u00f6gren syndrome and gastric MALT lymphoma","volume":"144","author":"Garcia","year":"2017","journal-title":"Ann Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.revmed.2020.02.015_bib0120","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/ced.12674","article-title":"Amyophatic dermatomyositis presenting as a flagellated skin eruption with positive MDA5\u00a0antibodies and thyroid cancer: a real association?","volume":"40","author":"Molina-Ruiz","year":"2015","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.revmed.2020.02.015_bib0125","first-page":"1707","article-title":"Small cell lung carcinoma: staging, imaging, and treatment considerations","volume":"34","author":"Carter","year":"2014","journal-title":"Radiogr Rev Publ Radiol Soc N Am Inc"},{"issue":"11","key":"10.1016\/j.revmed.2020.02.015_bib0130","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10495-014-1030-z","article-title":"Inhibition of the JAK\/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC","volume":"19","author":"Hu","year":"2014","journal-title":"Apoptosis Int J Program Cell Death"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320300813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866320300813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:42:23Z","timestamp":1759336943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866320300813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0248866320300813"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2020.02.015","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatomyosite \u00e0 anticorps anti-MDA5\u00a0s\u00e9v\u00e8re associ\u00e9e \u00e0 un cancer et contr\u00f4l\u00e9e par inhibiteur de JAK","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2020.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}